Schedule 13G ownership disclosure

MILESTONE PHARMACEUTICALS IN

Common Shares · CUSIP: 59935V107

Event date: 2026-03-20

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Trails Edge Capital Partners, LP

    Shares: 5,333,333.00 · Class: 4.3%

  • Trails Edge Biotechnology Master Fund, LP

    Shares: 5,333,333.00 · Class: 4.3%

  • Ortav Yehudai

    Shares: 5,333,333.00 · Class: 4.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001493152-26-013007
Form type
SCHEDULE 13G/A
Filer
Milestone Pharmaceuticals Inc.
CIK
CIK 1408443
Filed
Mar 26, 2026
Reporting period
Mar 20, 2026
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub